Lukas Langenegger, CEO
Lukas is one of the founders of hemotune. He is passionate about working at the interface of economics and research and strives to bring life-saving technologies from the laboratory bench to clinics. After completing a banking apprenticeship and working for two years at UBS, Lukas decided to study Chemical- and Bioengineering at ETH Zurich and MIT. Lukas holds a M.Sc. degree in Chemical- and Bioengineering from ETH Zurich and a diploma from the Swiss Bankers Association.
Dr. Carlos Mora, CSO
Carlos is one of the founders of hemotune. His interdisciplinary background in microbiology, immunology and bioengineering allows him to perfectly complement the hemotune team. During his doctoral studies at ETH Zurich, Carlos focused on the behavior and interaction of magnetic and non-magnetic nanoparticles in biological systems. He holds a Ph.D. degree in Chemical- and Bioengineering, as well as a M.Sc. degree in Microbiology and Immunology, both from ETH Zurich, Switzerland.
Dr. Jean-Claude Metzger, Head of Product Development
Jean-Claude Metzger joined hemotune in December 2017 as Head of Product Development. He leads the development of hemotune’s blood purification device. Before joining the team, Jean-Claude worked as Department Project Leader at Roche Diagnostics. He was responsible for the hardware development of a post-analytics device for in-vitro diagnostics Jean-Claude holds both, a M.Sc. and Ph.D. in Mechanical Engineering from ETH Zurich.
Dr. Ursina Haltinner, Regulatory & Quality Manager
Ursina Haltinner joined hemotune in October 2018 as Regulatory and Quality Affairs Manager. Ursina brings along 10 years of experience in the health care industry. She started her career as Regulatory Affairs Manager in the product development center of Synthes GmbH. Besides the medical device industry, she also provided regulatory support to biotechnology and pharmaceutical companies, being in charge of the main markets such as the US and EU. Ursina holds a doctoral degree in veterinary medicine from Vetsuisse Faculty, Zurich.
Dr. Manuel Baumgartner, R&D Engineer
Manuel Baumgartner joined hemotune in November 2018 as an R&D Engineer. Manuel obtained his Ph.D. in Materials Science from ETH Zurich, where he worked on nanomagnetism and spintronics devices. At hemotune, he is part of the device development team, focusing on testing and measuring magnetic nanoparticles. His doctoral thesis was nominated for the 2018 ETH Medal for outstanding Ph.D. work.
Lorenz Poiger, R&D Engineer
Lorenz Poiger joined hemotune in March 2019 as an R&D Engineer. Lorenz holds a Bachelor’s degree from ZHAW in Mechanical Engineering majoring in Biomechanical Engineering. Throughout his studies, he developed and tested a lumbar spine disc implant for a customer in the medical field and gained experience in product development including prototyping and manufacturing.
Dr. Inga Nilsson, R&D Chemist
Inga Nilsson works at Wyss Zurich as part of an Innosuisse project with hemotune. She holds a Ph.D. in Chemistry from the University of Rostock, where she focused on the multi-step synthesis of biologically relevant oligosaccharides. Before joining hemotune, Inga worked as a postdoctoral fellow at the Novartis Institute for Biomedical Research in Emeryville, California, where she gained experience in bacteriology, chemical biology, and assay development. As an R&D Chemist, she assists in the development of the nanomagnets, including synthesis and functionalization.
Dr. Monika Dengler, Biomedical Scientist
Monika Dengler works at Wyss Zurich as part of an Innosuisse project with hemotune. As a Biomedical Scientist she is involved in the product development of the nanomagnets, thereby managing the preclinical functional performance and biocompatibility studies. Monika obtained her Ph.D. in Pharmaceutical Sciences from ETH Zurich, where she worked on liver enzymes relevant to xenobiotic metabolism. During her studies, she completed a series of toxicology courses and gained considerable expertise in molecular, cellular, and clinical toxicology, risk assessment, and safety pharmacology.
Lukas Huber, Chemical Process Engineer
Lukas Huber works at Wyss Zurich as part of an Innosuisse project with hemotune. As a Chemical Process Engineer he assists in the development and production of the nanomagnets. Before joining this hemotune, Lukas worked at Empa, where he was responsible for the pyrolysis and activation of nitrogen-doped carbon xerogels, as well as for the upscaling of silica aerogels from lab scale to pilot scale. Lukas holds a M.Sc. degree from ETH Zurich in Materials Science.
BOARD OF DIRECTORS
President of the Board
Didier Cowling joined hemotune as President of the Board of Directors in 2019. He started his career as an investment analyst, first at Nomura and then at HSBC, forming a highly rated pharma and medtech team. He then moved into industry to be Director of Business Development at Phairson Medical Ltd. In 2000, he co-founded Kuros Therapeutics AG, which was successfully sold in 2002. Subsequently, he co-founded Kuros Biosurgery AG, which worked on developing a number of drug/device combination products. In early 2016, Kuros Biosurgery merged with Cytos Biotechnology and was renamed Kuros Biosciences AG, becoming public on the Swiss Exchange. Didier retired as President & CEO of the Kuros group in 2018 and is now working with a number of SMEs in the life science space, helping them to form and grow, both as an advisor and at Board level. As a serial entrepreneur and board member with over 30 years of broad experience in the field, Didier brings to hemotune his deep knowledge of the medtech industry and hands-on start-up experience.
Perry van Rijsingen
Perry van Rijsingen, through his company “21st Century Business Growth Advisors”, is Adviser, Independent Board Member, Horizon 2020 Business Coach and interim CEO. He also provides strategic advice to the Dutch high-tech company Sioux to help them develop their Healthcare business. In 2019 he joined the Board of Directors of Hemotune as Independent Board Member. Before, Perry was CEO of 2 large businesses at Philips and was responsible for Philips corporate venturing for 10 years, reporting directly to its Board of Management. In this latter role he led, commercialized & coached many start-ups & scale-ups in healthcare. In the process, he created new business models, markets & eco-systems, yielding triple digit growth and significant strategic & enterprise value for Philips. Perry, following his 35 years career, provides perspective beyond the textbooks. And he is one of the few international executives with a strong track record of successful leadership, innovation, commercialization and strategy in large/mature businesses and start-ups, with a deep understanding of how to succeed in both worlds. He brings deep knowledge in Medtech and Big Data.
CEO, Board Member
Dr. Carlos Mora
CSO, Board Member
Prof. Dr. Wendelin Jan Stark
Ph.D., ETH Zurich
Prof. Stark is a leading scientist in the field of nanotechnology and is currently Professor at the Institute of Chemical and Bioengineering and head of the Functional Materials Laboratory at ETH Zurich. He has published about 300 scientific articles and is co-founder of several spin off companies.
Prof. Dr. Robert Grass
Ph.D., Turbobeads GmbH
Prof. Grass is an expert in development and manufacturing of magnetic nanoparticles he is co-founder and CEO of turbobeads PLC, which manufactures and sells magnetic nanoparticles for research and industrial applications. He is also Professor at ETH Zurich.
Prof. Dr. Inge Herrmann
Ph.D., Empa & ETH Zurich
Prof. Herrmann is an expert in medical applications of magnetic nanoparticles. She has authored several publications in magnetic blood purification and is currently group leader at the Swiss Federal Laboratories for Material Science and Technnology (Empa) and Assistant Professor at ETH Zurich.
We envision a future where the deep understanding of diseases allows targeted interventions for the most challenging medical needs. By being technology leaders in highly specific blood purification, hemotune provides the means to treat critically ill patients and save lives.